Detalle Publicación

ARTÍCULO

Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19

Autores: Fragiel, M.; Miró, O.; Llorens, P.; Jiménez, S.; Piñera, P.; Burillo, G.; Martín, A.; Martín-Sánchez, F.J.; García-Lamberechts, E.J.; Jacob, J.; Alquézar-Arbé, A.; Juárez, J.; Jiménez, B.; Del Rio, R.; Mateo Roca, M.; García, A.H.; López Laguna, Nieves; Lopez Diez, M.P.; Pedraza García, J.; Fernández de Simón Almela, A.; Lopez Diaz, J.J.; Eiroa Hernández, P.; Ruiz de Lobera, N.; Porta-Etessam, J.; Fernández Pérez, C.; Calvo, C.; González Del Castillo, J. (Autor de correspondencia); Spanish Investigators in Emergency Situations Team
Título de la revista: ANNALS OF NEUROLOGY
ISSN: 0364-5134
Volumen: 89
Número: 3
Páginas: 598 - 603
Fecha de publicación: 2021
Resumen:
We diagnosed 11 Guillain-Barré syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15¿) than non-COVID (0.02¿) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS.
DOI: https://doi.org/10.1002/ana.25987
Impacto:
Google Scholar